| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01662895 Details | 2019-06-12 Interventional | 2 | 42 | Deferoxamine Cerebral Hemorr… Hemorrhage Intracerebral H… | By DSMB on October 18, 2013 due to increased incidence of ARDS. See modified protocol
[NCT02175225 The study was terminated prematurely, and only 42 subjects were enrolled. As a result, any formal evaluation of these outcomes would be under-powered. Only descriptive statistics are provided. | |||
| NCT00731874 Details | 2019-06-12 Interventional | 4 | 34 | Tacrolimus Immunosuppressi… | A higher rate of late rejection was seen in the low tacrolimus arm. The population reported is small because the study was stopped early due to the increase in late antibody mediated rejection (occurring after month 15) that was seen in Arm 2 (target tacrolimus trough 3 to 5 ng/mL). | |||
| NCT03697239 Details | 2019-06-11 Interventional | 1/2 | 0 | Albumin-Bound P… Ascorbic Acid Gemcitabine Paclitaxel Adenocarcinoma Pancreatic Neop… Metastatic Panc… Pancreas Cancer Pancreatic Aden… Pancreatic Canc… Pancreatic Duct… Pancreatic Meta… | FDA indicated the same study could not be conducted under multiple INDs - | |||
| NCT02147834 Details | 2019-06-11 Interventional | 2 | 5 | Ranolazine Angina | due to futility - | |||
| NCT02769065 Details | 2019-06-10 Interventional | 1 | 179 | Donepezil Alzheimer Disea… Cognitive Dysfu… Healthy Volunte… | Terminated prematurely as data from cohort no longer needed due to indication change. - | |||
| NCT00968968 Details | 2019-06-10 Interventional | 3 | 37 | Lapatinib Trastuzumab Cancer | - This study was closed to further enrollment since the enrollment rate would not allow the study to complete enrollment within an acceptable timeframe. | |||
| NCT03299387 Details | 2019-06-06 Interventional | 4 | 0 | Gentamicins Nitrofurantoin Communicable Di… Infections Urinary Tract I… | Study never recruited - | |||
| NCT01920477 Details | 2019-06-06 Interventional | 3 | 35 | Ofatumumab Pemphigus Pemphigus Vulga… | Novartis has acquired the rights to ofatumumab and terminated the OPV116910 and OPV117059
studies. This decision is not linked to any safety consideration. - | |||
| NCT03571594 Details | 2019-06-05 Interventional | 1 | 76 | Octreotide Acromegaly | The study met a pre-defined protocol study stopping criteria - | |||
| NCT03468543 2017-000982-61 Details | 2019-06-05 Interventional | 1 | 3 | Memantine Gastric Retenti… Healthy | Per protocol stopping rules The trial was prematurely ended after the dosing of three subjects. | |||
| NCT03099161 Details | 2019-06-05 Interventional | 1 | 10 | Pembrolizumab Neoplasm | The data did not support study endpoints This study was terminated early because the data did not support the study endpoints. | |||
| NCT02398500 2014-005214-37 Details | 2019-06-05 Interventional | 1/2 | 25 | Ranibizumab Macular Degener… Age-related Mac… | Management decision - | |||
| NCT01862263 Details | 2019-06-05 Interventional | 4 | 191 | Vildagliptin Diabetes Mellit… Diabetes Mellit… Type 2 Diabetes… | - - | |||
| NCT01582152 Details | 2019-06-05 Interventional | 1/2 | 12 | Bevacizumab Brain Neoplasms Central Nervous… Glioblastoma Neoplasms Nervous System … | Phase 2 part of the trial will no longer continue since the protocol competes with another
TPI287 protocol in outside institution supported by the sponsor. - | |||
| NCT00524173 Details | 2019-06-05 Interventional | 2 | 35 | Emtricitabine Tenofovir Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch… | - - | |||
| NCT02585479 Details | 2019-06-04 Interventional | 2/3 | 0 | Ethiodized Oil Gelatin Sponge,… Oxaliplatin Pirarubicin Carcinoma Carcinoma, Hepa… Hepatocellular … | It doesn't meet the requirements of randomized trials - | |||
| NCT02534337 Details | 2019-06-04 Interventional | 2/3 | 0 | Fluorouracil Gemcitabine Leucovorin Oxaliplatin Carcinoma Carcinoma, Hepa… Hepatocellular … | It doesn't meet the requirements of randomized trials - | |||
| NCT02527772 Details | 2019-06-04 Interventional | 2/3 | [2 Refs] | 0 | Doxorubicin Fluorouracil Gemcitabine Leucovorin Liposomal doxor… Oxaliplatin Carcinoma Carcinoma, Hepa… Hepatocellular … | It doesn't meet the requirements of randomized trials - | ||
| NCT02490774 2013-003980-74 Details | 2019-06-04 Interventional | 2 | 174 | Levonorgestrel Contraception | - - | |||
| NCT01748240 2012-001401-25 Details | 2019-06-04 Interventional | 2 | 21 | Azacitidine Vorinostat Myelodysplastic… Preleukemia Syndrome Myelodysplastic… | inefficiency - |